BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38151661)

  • 21. A retrospective analysis on the management of pigmented lesions using a picosecond 755-nm alexandrite laser in Asians.
    Chan JC; Shek SY; Kono T; Yeung CK; Chan HH
    Lasers Surg Med; 2016 Jan; 48(1):23-9. PubMed ID: 26696500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma.
    Shihab N; Prihartono J; Tovar-Garza A; Agustin T; Legiawati L; Pandya AG
    Australas J Dermatol; 2020 Aug; 61(3):237-242. PubMed ID: 32109318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laser-assisted delivery of tranexamic acid for melasma: Pilot study using a novel 1927 nm fractional thulium fiber laser.
    Wang JV; Christman MP; Feng H; Ferzli G; Jeon H; Geronemus RG
    J Cosmet Dermatol; 2021 Jan; 20(1):105-109. PubMed ID: 33174686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melasma: A critical analysis of clinical trials investigating treatment modalities published in the past 10 years.
    Spierings NMK
    J Cosmet Dermatol; 2020 Jun; 19(6):1284-1289. PubMed ID: 31603285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma.
    Banihashemi M; Zabolinejad N; Jaafari MR; Salehi M; Jabari A
    J Cosmet Dermatol; 2015 Sep; 14(3):174-7. PubMed ID: 26177992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treating melasma: A split-face comparative clinical, histopathological, and antera 3D camera study.
    El-Husseiny R; Rakha N; Sallam M
    Dermatol Ther; 2020 Nov; 33(6):e14240. PubMed ID: 32856757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of laser and topical tranexamic acid combination therapy in melasma: An updated systematic review and meta-analysis of randomized controlled trials.
    Khan QA; Abdi P; Farkouh C; Anthony MR; Chundru A; Amatul F; Parimi K; Santiago N; Farkouh M; Iram S; Khan A
    Lasers Med Sci; 2023 Jun; 38(1):139. PubMed ID: 37326860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of melasma with mixed parameters of 1,064-nm Q-switched Nd:YAG laser toning and an enhanced effect of ultrasonic application of vitamin C: a split-face study.
    Lee MC; Chang CS; Huang YL; Chang SL; Chang CH; Lin YF; Hu S
    Lasers Med Sci; 2015 Jan; 30(1):159-63. PubMed ID: 25073866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral tranexamic acid, hydroquinone 4% and low-fluence 1064 nm Q-switched Nd:YAG laser for mixed melasma: Clinical and dermoscopic evaluation.
    Elkamshoushi AM; Romisy D; Omar SS
    J Cosmet Dermatol; 2022 Feb; 21(2):657-668. PubMed ID: 33826785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Photoaging Reversibility in Asian Patients With Melasma Treated Using Picosecond Lasers With a Diffractive Lens Array: A 1-Year Prospective Observational Cohort Study.
    Lin ET; Chiang HM; Lin BS; Huang YH; Chang CC
    Dermatol Surg; 2021 Jan; 47(1):e10-e14. PubMed ID: 32271179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 755-nm picosecond alexandrite laser versus 1064-nm Q-switched Nd:YAG laser for melasma: A randomized, split-face controlled, 2-year follow-up study.
    Zhou Y; Li Y; Hamblin MR; Wen X
    Lasers Surg Med; 2024 Mar; 56(3):263-269. PubMed ID: 38282099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of efficacy and safety of tranexamic acid mesotherapy versus oral tranexamic acid in patients with melasma undergoing Q-switched fractional 1064-nm Nd:YAG laser: A blinded RCT and follow-up.
    Behrangi E; Shemshadi M; Ghassemi M; Goodarzi A; Dilmaghani S
    J Cosmet Dermatol; 2022 Jan; 21(1):279-289. PubMed ID: 34724323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A split face study to document the safety and efficacy of clearance of melasma with a 5 ns q switched Nd YAG laser versus a 50 ns q switched Nd YAG laser.
    Alsaad SM; Ross EV; Mishra V; Miller L
    Lasers Surg Med; 2014 Dec; 46(10):736-40. PubMed ID: 25411141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melasma treatment with a 1064 nm, picosecond-domain laser with a fractionated multibeam lens array.
    Bernstein EF; Basilavecchio LD; Wang J
    Lasers Surg Med; 2023 Nov; 55(9):801-808. PubMed ID: 37668307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of 577 nm pro-yellow laser in the treatment of melasma: a prospective split-face study.
    Mohamed EM; Younes AH; Hussein GM
    J Cosmet Laser Ther; 2020 Feb; 22(2):107-110. PubMed ID: 32216566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of combined fractional CO
    Tawfic SO; Abdel Halim DM; Albarbary A; Abdelhady M
    Lasers Surg Med; 2019 Jan; 51(1):27-33. PubMed ID: 30431171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microneedling-assisted topical tranexamic acid solution versus 4% hydroquinone for treating melasma: A split-face randomized study.
    Zaky MS; Obaid ZM; Khalil EA; Elsaie ML
    J Cosmet Dermatol; 2021 Dec; 20(12):4011-4016. PubMed ID: 34525492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
    Kaufman BP; Alexis AF
    J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of microneedling plus topical 4% tranexamic acid solution vs 4% hydroquinone in the treatment of melasma: A single-blind randomized clinical trial.
    Shamsi Meymandi S; Mozayyeni A; Shamsi Meymandi M; Aflatoonian M
    J Cosmet Dermatol; 2020 Nov; 19(11):2906-2911. PubMed ID: 32406162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial.
    Adalatkhah H; Sadeghi-Bazargani H
    Drug Des Devel Ther; 2015; 9():4219-25. PubMed ID: 26345129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.